The new definition of dry eye as well as a new classification system are contained in the Film & Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS II) report which was published on July 21, 2017. It has impacted the way the disease is diagnosed
and examined.
THE UPDATED DEFINITION1
“Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.”
- The management of dry eye disease (DED) remains something of an art, not easily
lending itself to a rigid, evidence-based algorithm that accommodates all patients with
dry eye symptoms and signs. - For patients who do not respond to a given level of management, or who exhibit more
severe DED, may need extra management and in some cases, the previous therapy
may be continued, in addition to any new therapies. - The VISUfarma portfolio offers a variety of products to help manage different types of
symptoms caused by dry eye disease and their management.